Call for Papers

Cancer Biotherapy and Radiopharmaceuticals

Special Issue on Cancer Immunotherapeutics

Cancer Biotherapy and Radiopharmaceuticals is currently seeking high-quality, innovative submissions on cancer immunotherapies to be published in a special collection on the topic. Submissions are accepted in the form of original research, reviews, methods, and other original content.

Areas of research focus include, but are not limited to:

  • Cancer immunology
  • Synthetic immunology
  • T Cell receptor mimics
  • Pattern recognition receptor agonists
  • CART therapy
  • Immune checkpoint inhibitors

Contributions will receive prompt and thorough peer review and will be published online ahead of print after acceptance.

Please refer to our Instructions for Authors before submitting your manuscript for consideration.

Deadline for Manuscript Submission: July 15, 2017

Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal with 30 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies.

Advantages of publishing in the Journal include:

  • Rapid, high-quality peer review
  • Open Access options available
  • Fast and user-friendly electronic submission
  • Maximum exposure: accessible in 170 countries worldwide

Learn More about this journal

Deadline for Manuscript Submission:
July 15, 2017


For questions, please contact Editor Dr. Don Buchsbaum